Table 1.
CVST-VITT patients treated with endovascular treatment.
| EVT (n = 18) | Missing n (%) | No EVT (n = 118) | |
|---|---|---|---|
| Demographic characteristics | |||
| Women, n (%) | 15 (83) | - | 87 (74) |
| Age, in years, median (IQR) | 39 (28–45) | - | 45 (28–56) |
| SARS-CoV-2 vaccination details | - | ||
| ChAdOx1 nCoV-19, n (%) | 17 (94) | 92 (78) | |
| Sinovac, n (%) | 1 (6) | 3 (2.5) | |
| Other, n (%) | 0 | 12 (10) | |
| Days from vaccination to CVST symptom onset, median (IQR) | 8 (7–10) | - | 9 (7–11) |
| Clinical characteristics at presentation | |||
| Headache, n (%) | 18 (100) | - | 108 (92) |
| Focal neurological deficits, n (%) | 14 (78) | - | 62 (54) |
| Seizure, n (%) | 5 (28) | 16 (14) | |
| Coma, n (%) | 5 (35) | 1 (6) | 22 (20) |
| Second VTE at presentation | 4 (27) | 3 (17) | 24 (21) |
| Laboratory values at presentation | |||
| Platelet count (×103/μL), median (IQR) | 42 (28–76) | - | 55 (30–84) |
| D-dimer (mg FEU/L), median (IQR) | 20 (11–35) | 2 (11) | 20 (8–28) |
| Fibrinogen (g/L), median (IQR) | 1.5 (0.8–2.4) | 2 (11) | 2.1 (1.3–2.8) |
| Platelet Factor 4 antibodies, n (%) | 13 (87) | 3 (17) | 83 (91) |
| Imaging at presentation | |||
| Non-hemorrhagic lesion, n (%) | 7 (39) | - | 29 (26) |
| Hemorrhagic lesion, n (%) | 15 (88) | 1 (6) | 74 (64) |
| Thrombus load, median (IQR) | 4.5 (3–5.75) | - | 3 (1.25–3) |
CVST: cerebral venous sinus thrombosis; EVT: endovascular treatment; FEU: fibrinogen equivalent units; IQR: interquartile range; VITT: vaccine-induced immune thrombotic thrombocytopenia; VTE: venous thromboembolism.